Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bmab1700 vs Opdivo in Resected Melanoma
NCT07476326Phase 1Recruiting
- Sponsor
- Mylan
- Start
- Sep 2026
- Primary completion
- Aug 2027
- Modality
- Monoclonal Antibodies
- Countries
- 10
01
Overview
Phase 1, randomised, double-blind trial of Bmab1700 in melanoma (2 arms), sponsored by Mylan. Primary endpoints: Area Under the Concentration-Time Curve from Time 0 to Day 29 and Area Under the Concentration-Time Curve Over a Dosing Interval. Started Sep 2026; status: recruiting.
02
Drugs
Bmab1700
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT07476326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07476326.